Online inquiry

IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9589MR)

This product GTTS-WQ9589MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets VSIR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_022153.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 64115
UniProt ID Q9H7M9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9589MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2757MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG162
GTTS-WQ11420MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ9833MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JTX-2011
GTTS-WQ103MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 1121B
GTTS-WQ312MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 19D12
GTTS-WQ8647MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ4867MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BTCT4465A
GTTS-WQ8813MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IBI-308
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW